Natural History Study of Biomarkers in Pulmonary Arterial Hypertension

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-100
SponsorNational Institutes of Health Clinical Center (CC)

About this trial

Background:

\- High blood pressure in the lungs, known as pulmonary arterial hypertension (PAH), is a rare disorder. Some people have disease-associated PAH and some have PAH from an unknown cause. Researchers want to follow the natural history of all PAH patients to understand how PAH progresses in order to discover targets for future research into new treatments. To further identify treatment targets, they will compare healthy volunteers to patients with PAH.

Objectives:

\- To study the natural history of PAH.

Eligibility:

* Individuals at least 18 years of age who have PAH. * Healthy volunteers at least 18 years of age.

Design:

* Participants with PAH will have periodic visits to the National Institutes of Health Clinical Center. After the first visit, they will return in 6 months and then yearly or every other year for as long as the study continues. * The first visit will take up to 3 days. It will involve the following tests: * Physical exam and medical history * Blood and urine samples * Heart and lung function tests and imaging studies * Six-minute walk test * Questions about exercise and physical activity * Healthy volunteers will have only one visit to the Clinical Center, during which they will undergo screening tests, and complete many of the same tests as patients with PAH

Eligibility criteria

Qualifiers

None

Disqualifiers

mean pulmonary artery pressure of > 25 mmHg at rest,

pulmonary capillary wedge pressure of < 15 mmHg (or a left ventricular end-diastolic pressure of < 12 mmHg), and

pulmonary vascular resistance of > 3 Wood units (240 dyn s cm-5).

Pregnant or breastfeeding women (all women of childbearing potential will be required to have a screening urine or blood pregnancy test)

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

270 Participants
are grouped into 2 trial groups